A detailed history of Drw Securities, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Drw Securities, LLC holds 50,000 shares of BMY stock, worth $2.89 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
50,000
Holding current value
$2.89 Million
% of portfolio
0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $89,050 - $100,966
1,856 Added 14.58%
14,585 $790,000
Q4 2023

Feb 16, 2024

BUY
$48.48 - $57.85 $423,715 - $505,609
8,740 Added 219.1%
12,729 $653,000
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $52,795 - $59,033
-912 Reduced 18.61%
3,989 $232,000
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $400,162 - $444,317
-6,281 Reduced 56.17%
4,901 $313,000
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $734,769 - $833,394
11,182 New
11,182 $775,000
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $655,032 - $721,419
-9,020 Reduced 76.74%
2,734 $211,000
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $367,834 - $441,066
5,983 Added 103.67%
11,754 $858,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $309,498 - $360,802
5,771 New
5,771 $360,000
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $409,988 - $480,248
-6,929 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$61.91 - $67.42 $428,974 - $467,153
6,929 New
6,929 $463,000
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $2.41 Million - $2.82 Million
-44,053 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$46.4 - $67.43 $2.04 Million - $2.97 Million
44,053 New
44,053 $2.45 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $1.37 Million - $1.58 Million
-22,944 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $1.38 Million - $1.5 Million
22,944
22,944 $1.41 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Drw Securities, LLC Portfolio

Follow Drw Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Drw Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Drw Securities, LLC with notifications on news.